Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jaffee, E. M.
Right arrow Articles by Yeo, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jaffee, E. M.
Right arrow Articles by Yeo, C. J.
Journal of Clinical Oncology, Vol 19, Issue 1 (January), 2001: 145-156
© 2001 American Society for Clinical Oncology

Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation

By Elizabeth M. Jaffee, Ralph H. Hruban, Barbara Biedrzycki, Daniel Laheru, Karen Schepers, Patricia R. Sauter, Marti Goemann, Joanne Coleman, Louise Grochow, Ross C. Donehower, Keith D. Lillemoe, Seamus O’Reilly, Ross A. Abrams, Drew M. Pardoll, John L. Cameron, Charles J. Yeo

From the Departments of Oncology, Surgery, and Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD.

Address reprint requests to Elizabeth Jaffee, MD, The Johns Hopkins University, The Bunting-Blaustein Cancer Research Building, Room 4M07, 1650 Orleans St, Baltimore, MD 21231; email ejaffee@ jhmi.edu.

PURPOSE: Allogeneic granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting tumor vaccines can cure established tumors in the mouse, but their efficacy against human tumors is uncertain. We have developed a novel GM-CSF–secreting pancreatic tumor vaccine. To determine its safety and ability to induce antitumor immune responses, we conducted a phase I trial in patients with surgically resected adenocarcinoma of the pancreas.

PATIENTS AND METHODS: Fourteen patients with stage 1, 2, or 3 pancreatic adenocarcinoma were enrolled. Eight weeks after pancreaticoduodenectomy, three patients received 1 x 107 vaccine cells, three patients received 5 x 107 vaccine cells, three patients received 10 x 107 vaccine cells, and five patients received 50 x 107 vaccine cells. Twelve of 14 patients then went on to receive a 6-month course of adjuvant radiation and chemotherapy. One month after completing adjuvant treatment, six patients still in remission received up to three additional monthly vaccinations with the same vaccine dose that they had received originally.

RESULTS: No dose-limiting toxicities were encountered. Vaccination induced increased delayed-type hypersensitivity (DTH) responses to autologous tumor cells in three patients who had received >= 10 x 107 vaccine cells. These three patients also seemed to have had an increased disease-free survival time, remaining disease-free at least 25 months after diagnosis.

CONCLUSION: Allogeneic GM-CSF–secreting tumor vaccines are safe in patients with pancreatic adenocarcinoma. This vaccine approach seems to induce dose-dependent systemic antitumor immunity as measured by increased postvaccination DTH responses against autologous tumors. Further clinical evaluation of this approach in patients with pancreatic cancer is warranted.




This article has been cited by other articles:


Home page
 JCOHome page
T. Sato, D. J. Eschelman, C. F. Gonsalves, M. Terai, I. Chervoneva, P. A. McCue, J. A. Shields, C. L. Shields, A. Yamamoto, D. Berd, et al.
Immunoembolization of Malignant Liver Tumors, Including Uveal Melanoma, Using Granulocyte-Macrophage Colony-Stimulating Factor
J. Clin. Oncol., November 20, 2008; 26(33): 5436 - 5442.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
R. A. Wolff, G. R. Varadhachary, and D. B. Evans
Adjuvant Therapy for Adenocarcinoma of the Pancreas: Analysis of Reported Trials and Recommendations for Future Progress
Ann. Surg. Oncol., October 1, 2008; 15(10): 2773 - 2786.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Tsuruta, L. Pereboeva, M. Breidenbach, D. T. Rein, M. Wang, R. D. Alvarez, G. P. Siegal, P. Dent, P. B. Fisher, and D. T. Curiel
A Fiber-Modified Mesothelin Promoter-Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer
Clin. Cancer Res., June 1, 2008; 14(11): 3582 - 3588.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
S Serba, J Schmidt, N Wentzensen, E Ryschich, and A Marten
Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma
Gut, March 1, 2008; 57(3): 344 - 351.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
G. Feldmann and A. Maitra
Molecular Genetics of Pancreatic Ductal Adenocarcinomas and Recent Implications for Translational Efforts
J. Mol. Diagn., March 1, 2008; 10(2): 111 - 122.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Laheru, E. Lutz, J. Burke, B. Biedrzycki, S. Solt, B. Onners, I. Tartakovsky, J. Nemunaitis, D. Le, E. Sugar, et al.
Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
Clin. Cancer Res., March 1, 2008; 14(5): 1455 - 1463.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Li, U. Bharadwaj, R. Zhang, S. Zhang, H. Mu, W. E. Fisher, F. C. Brunicardi, C. Chen, and Q. Yao
Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer
Mol. Cancer Ther., February 1, 2008; 7(2): 286 - 296.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Sabbatini and K. Odunsi
Immunologic Approaches to Ovarian Cancer Treatment
J. Clin. Oncol., July 10, 2007; 25(20): 2884 - 2893.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. J. Small, N. Sacks, J. Nemunaitis, W. J. Urba, E. Dula, A. S. Centeno, W. G. Nelson, D. Ando, C. Howard, F. Borellini, et al.
Granulocyte Macrophage Colony-Stimulating Factor-Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer
Clin. Cancer Res., July 1, 2007; 13(13): 3883 - 3891.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Ho, T. K. Bera, M. C. Willingham, M. Onda, R. Hassan, D. FitzGerald, and I. Pastan
Mesothelin Expression in Human Lung Cancer
Clin. Cancer Res., March 1, 2007; 13(5): 1571 - 1575.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G Parmiani, C Castelli, L Pilla, M Santinami, M. Colombo, and L Rivoltini
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
Ann. Onc., February 1, 2007; 18(2): 226 - 232.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Li, A. S. Lalani, T. C. Harding, B. Luan, K. Koprivnikar, G. Huan Tu, R. Prell, M. J. VanRoey, A. D. Simmons, and K. Jooss
Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a GM-CSF-Secreting Cancer Immunotherapy.
Clin. Cancer Res., November 15, 2006; 12(22): 6808 - 6816.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. W. Simons, M. A. Carducci, B. Mikhak, M. Lim, B. Biedrzycki, F. Borellini, S. M. Clift, K. M. Hege, D. G. Ando, S. Piantadosi, et al.
Phase I/II Trial of an Allogeneic Cellular Immunotherapy in Hormone-Naive Prostate Cancer.
Clin. Cancer Res., June 1, 2006; 12(11): 3394 - 3401.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
X. Duan, H. Hisaeda, J. Shen, L. Tu, T. Imai, B. Chou, S. Murata, T. Chiba, K. Tanaka, H. J. Fehling, et al.
The ubiquitin-proteasome system plays essential roles in presenting an 8-mer CTL epitope expressed in APC to corresponding CD8+ T cells
Int. Immunol., May 1, 2006; 18(5): 679 - 687.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. I. Garbe, B. Vermeer, J. Gamrekelashvili, R. v. Wasielewski, F. R. Greten, A. M. Westendorf, J. Buer, R. M. Schmid, M. P. Manns, F. Korangy, et al.
Genetically Induced Pancreatic Adenocarcinoma Is Highly Immunogenic and Causes Spontaneous Tumor-Specific Immune Responses
Cancer Res., January 1, 2006; 66(1): 508 - 516.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Okada, M. Akada, T. Fujita, T. Iwata, Y. Goto, K. Kido, T. Okada, Y. Matsuzaki, K. Kobayashi, S. Matsuno, et al.
A Novel Cancer Testis Antigen That Is Frequently Expressed in Pancreatic, Lung, and Endometrial Cancers
Clin. Cancer Res., January 1, 2006; 12(1): 191 - 197.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. M. Luiten, E. W.M. Kueter, W. Mooi, M. P.W. Gallee, E. M. Rankin, W. R. Gerritsen, S. M. Clift, W. J. Nooijen, P. Weder, W. F. van de Kasteele, et al.
Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF-Transduced Tumor Cells in Metastatic Melanoma Patients
J. Clin. Oncol., December 10, 2005; 23(35): 8978 - 8991.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
G. Y. Yang, T. D. Wagner, M. Fuss, and C. R. Thomas Jr.
Multimodality Approaches for Pancreatic Cancer
CA Cancer J Clin, November 1, 2005; 55(6): 352 - 367.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. A. Laheru, D. M. Pardoll, and E. M. Jaffee
Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology
Mol. Cancer Ther., November 1, 2005; 4(11): 1645 - 1652.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. A. Emens and E. M. Jaffee
Leveraging the Activity of Tumor Vaccines with Cytotoxic Chemotherapy
Cancer Res., September 15, 2005; 65(18): 8059 - 8064.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. Gandini, A. B. Lowenfels, E. M. Jaffee, T. D. Armstrong, and P. Maisonneuve
Allergies and the Risk of Pancreatic Cancer: A Meta-analysis with Review of Epidemiology and Biological Mechanisms
Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 1908 - 1916.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Mosolits, G. Ullenhag, and H. Mellstedt
Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results
Ann. Onc., June 1, 2005; 16(6): 847 - 862.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. A. Prell, B. Li, J. M. Lin, M. VanRoey, and K. Jooss
Administration of IFN-{alpha} Enhances the Efficacy of a Granulocyte Macrophage Colony Stimulating Factor-Secreting Tumor Cell Vaccine
Cancer Res., March 15, 2005; 65(6): 2449 - 2456.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
L A Emens, R T Reilly, and E M Jaffee
Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity
Endocr. Relat. Cancer, March 1, 2005; 12(1): 1 - 17.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Zhou, D. Y. Jun, A. M. Thomas, X. Huang, L.-Q. Huang, J. Mautner, W. Mo, P. F. Robbins, D. M. Pardoll, and E. M. Jaffee
Diverse CD8+ T-Cell Responses to Renal Cell Carcinoma Antigens in Patients Treated with an Autologous Granulocyte-Macrophage Colony-Stimulating Factor Gene-Transduced Renal Tumor Cell Vaccine
Cancer Res., February 1, 2005; 65(3): 1079 - 1088.
[Abstract] [Full Text] [PDF]

Home page
 Cold Spring Harb Symp Quant BiolHome page
D.A. TUVESON and S.R. HINGORANI
Ductal Pancreatic Cancer in Humans and Mice
Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 65 - 72.
[Abstract] [PDF]

Home page
 JEMHome page
A. M. Thomas, L. M. Santarsiero, E. R. Lutz, T. D. Armstrong, Y.-C. Chen, L.-Q. Huang, D. A. Laheru, M. Goggins, R. H. Hruban, and E. M. Jaffee
Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients
J. Exp. Med., August 2, 2004; 200(3): 297 - 306.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Hassan, T. Bera, and I. Pastan
Mesothelin: A New Target for Immunotherapy
Clin. Cancer Res., June 15, 2004; 10(12): 3937 - 3942.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Y. Mapara and M. Sykes
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
J. Clin. Oncol., March 15, 2004; 22(6): 1136 - 1151.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. M. Coughlin, B. A. Vance, S. A. Grupp, and R. H. Vonderheide
RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy
Blood, March 15, 2004; 103(6): 2046 - 2054.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
C Schneider, T Schmidt, C Ziske, K Tiemann, K-M Lee, V Uhlinsky, P Behrens, T Sauerbruch, I G H Schmidt-Wolf, P F Muhlradt, et al.
Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model
Gut, March 1, 2004; 53(3): 355 - 361.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Iacobuzio-Donahue, J. Song, G. Parmiagiani, C. J. Yeo, R. H. Hruban, and S. E. Kern
Missense Mutations of MADH4: Characterization of the Mutational Hot Spot and Functional Consequences in Human Tumors
Clin. Cancer Res., March 1, 2004; 10(5): 1597 - 1604.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Nemunaitis, D. Sterman, D. Jablons, J. W. Smith II, B. Fox, P. Maples, S. Hamilton, F. Borellini, A. Lin, S. Morali, et al.
Granulocyte-Macrophage Colony-Stimulating Factor Gene-Modified Autologous Tumor Vaccines in Non-Small-Cell Lung Cancer
J Natl Cancer Inst, February 18, 2004; 96(4): 326 - 331.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. A. Iacobuzio-Donahue, R. Ashfaq, A. Maitra, N. V. Adsay, G. L. Shen-Ong, K. Berg, M. A. Hollingsworth, J. L. Cameron, C. J. Yeo, S. E. Kern, et al.
Highly Expressed Genes in Pancreatic Ductal Adenocarcinomas: A Comprehensive Characterization and Comparison of the Transcription Profiles Obtained from Three Major Technologies
Cancer Res., December 15, 2003; 63(24): 8614 - 8622.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Cuenca, F. Cheng, H. Wang, J. Brayer, P. Horna, L. Gu, H. Bien, I. M. Borrello, H. I. Levitsky, and E. M. Sotomayor
Extra-Lymphatic Solid Tumor Growth Is Not Immunologically Ignored and Results in Early Induction of Antigen-Specific T-Cell Anergy: Dominant Role of Cross-Tolerance to Tumor Antigens
Cancer Res., December 15, 2003; 63(24): 9007 - 9015.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Kochling, S. A. Konig-Merediz, R. Stripecke, D. Buchwald, A. Korte, H. G. von Einsiedel, F. Sack, G. Henze, K. Seeger, B. Wittig, et al.
Protection of Mice against Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia by Cell-based Vaccination Using Nonviral, Minimalistic Expression Vectors and Immunomodulatory Oligonucleotides
Clin. Cancer Res., August 1, 2003; 9(8): 3142 - 3149.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Davila, R. Kennedy, and E. Celis
Generation of Antitumor Immunity by Cytotoxic T Lymphocyte Epitope Peptide Vaccination, CpG-oligodeoxynucleotide Adjuvant, and CTLA-4 Blockade
Cancer Res., June 15, 2003; 63(12): 3281 - 3288.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
C. J. Yeo
The Recent Past and Future of Adjuvant Therapy for Pancreatic Cancer
Ann. Surg. Oncol., June 1, 2003; 10(5): 488 - 489.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. A. Iacobuzio-Donahue, A. Maitra, M. Olsen, A. W. Lowe, N. T. Van Heek, C. Rosty, K. Walter, N. Sato, A. Parker, R. Ashfaq, et al.
Exploration of Global Gene Expression Patterns in Pancreatic Adenocarcinoma Using cDNA Microarrays
Am. J. Pathol., April 1, 2003; 162(4): 1151 - 1162.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Salgia, T. Lynch, A. Skarin, J. Lucca, C. Lynch, K. Jung, F. S. Hodi, M. Jaklitsch, S. Mentzer, S. Swanson, et al.
Vaccination With Irradiated Autologous Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor Augments Antitumor Immunity in Some Patients With Metastatic Non-Small-Cell Lung Carcinoma
J. Clin. Oncol., February 15, 2003; 21(4): 624 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. D. Sandler, H. Chihara, G. Kobayashi, X. Zhu, M. A. Miller, D. L. Scott, and A. M. Krieg
CpG Oligonucleotides Enhance the Tumor Antigen-specific Immune Response of a Granulocyte Macrophage Colony-stimulating Factor-based Vaccine Strategy in Neuroblastoma
Cancer Res., January 15, 2003; 63(2): 394 - 399.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Curti, M. Parenza, and M. P. Colombo
Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma
Blood, January 15, 2003; 101(2): 568 - 575.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
I. D. Davis, M. Jefford, P. Parente, and J. Cebon
Rational approaches to human cancer immunotherapy
J. Leukoc. Biol., January 1, 2003; 73(1): 3 - 29.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Linardakis, A. Bateman, V. Phan, A. Ahmed, M. Gough, K. Olivier, R. Kennedy, F. Errington, K. J. Harrington, A. Melcher, et al.
Enhancing the Efficacy of a Weak Allogeneic Melanoma Vaccine by Viral Fusogenic Membrane Glycoprotein-mediated Tumor Cell-Tumor Cell Fusion
Cancer Res., October 1, 2002; 62(19): 5495 - 5504.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
I. Espinoza-Delgado
Cancer Vaccines
Oncologist, August 1, 2002; 7(90003): 20 - 33.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
S. Dermime, A. Armstrong, R. E Hawkins, and P. L Stern
Cancer vaccines and immunotherapy
Br. Med. Bull., July 1, 2002; 62(1): 149 - 162.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. A. Iacobuzio-Donahue, A. Maitra, G. L. Shen-Ong, T. van Heek, R. Ashfaq, R. Meyer, K. Walter, K. Berg, M. A. Hollingsworth, J. L. Cameron, et al.
Discovery of Novel Tumor Markers of Pancreatic Cancer using Global Gene Expression Technology
Am. J. Pathol., April 1, 2002; 160(4): 1239 - 1249.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Teshima, C. Liu, K. P. Lowler, G. Dranoff, and J. L. M. Ferrara
Donor Leukocyte Infusion from Immunized Donors Increases Tumor Vaccine Efficacy after Allogeneic Bone Marrow Transplantation
Cancer Res., February 1, 2002; 62(3): 796 - 800.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Argani, C. Iacobuzio-Donahue, B. Ryu, C. Rosty, M. Goggins, R. E. Wilentz, S. R. Murugesan, S. D. Leach, E. Jaffee, C. J. Yeo, et al.
Mesothelin Is Overexpressed in the Vast Majority of Ductal Adenocarcinomas of the Pancreas: Identification of a New Pancreatic Cancer Marker by Serial Analysis of Gene Expression (SAGE)
Clin. Cancer Res., December 1, 2001; 7(12): 3862 - 3868.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Argani, C. Rosty, R. E. Reiter, R. E. Wilentz, S. R. Murugesan, S. D. Leach, B. Ryu, H. G. Skinner, M. Goggins, E. M. Jaffee, et al.
Discovery of New Markers of Cancer through Serial Analysis of Gene Expression: Prostate Stem Cell Antigen Is Overexpressed in Pancreatic Adenocarcinoma
Cancer Res., June 1, 2001; 61(11): 4320 - 4324.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2001 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online